Panion & BF Biotech Inc
Panion & Bf Biotech Inc., a biotechnology pharmaceutical company, provides western medicines, cosmetics, testing reagents, food and chemical products in Taiwan, the United States, China, Hong Kong, Macau, and internationally. The company offers products in the areas of antibody, respiratory, gastrointestinal, COVID-19 IVD, antigen, anti-aging, active pharmaceutical ingredients, disease treatment,… Read more
Panion & BF Biotech Inc (1760) - Total Assets
Latest total assets as of September 2025: NT$3.12 Billion TWD
Based on the latest financial reports, Panion & BF Biotech Inc (1760) holds total assets worth NT$3.12 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Panion & BF Biotech Inc - Total Assets Trend (2009–2024)
This chart illustrates how Panion & BF Biotech Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Panion & BF Biotech Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Panion & BF Biotech Inc's total assets of NT$3.12 Billion consist of 47.1% current assets and 52.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 17.4% |
| Accounts Receivable | NT$367.89 Million | 11.5% |
| Inventory | NT$526.93 Million | 16.4% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$3.56 Million | 0.1% |
| Goodwill | NT$4.49 Million | 0.1% |
Asset Composition Trend (2009–2024)
This chart illustrates how Panion & BF Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Panion & BF Biotech Inc's current assets represent 47.1% of total assets in 2024, a decrease from 65.1% in 2009.
- Cash Position: Cash and equivalents constituted 17.4% of total assets in 2024, up from 15.4% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2009.
- Asset Diversification: The largest asset category is inventory at 16.4% of total assets.
Panion & BF Biotech Inc Competitors by Total Assets
Key competitors of Panion & BF Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Panion & BF Biotech Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Panion & BF Biotech Inc generates 0.63x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Panion & BF Biotech Inc generates $ 3.88 in net profit.
Panion & BF Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.41 | 1.42 | 1.54 |
| Quick Ratio | 0.84 | 0.88 | 0.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$401.09 Million | NT$ 417.04 Million | NT$ 508.36 Million |
Panion & BF Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Panion & BF Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.78 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -0.8% |
| Total Assets | NT$3.21 Billion |
| Market Capitalization | $123.88 Million USD |
Valuation Analysis
Below Book Valuation: The market values Panion & BF Biotech Inc's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Panion & BF Biotech Inc's assets decreased by 0.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Panion & BF Biotech Inc (2009–2024)
The table below shows the annual total assets of Panion & BF Biotech Inc from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$3.21 Billion | -0.84% |
| 2023-12-31 | NT$3.24 Billion | +4.58% |
| 2022-12-31 | NT$3.09 Billion | +4.76% |
| 2021-12-31 | NT$2.95 Billion | -3.93% |
| 2020-12-31 | NT$3.07 Billion | +60.73% |
| 2019-12-31 | NT$1.91 Billion | +4.23% |
| 2018-12-31 | NT$1.83 Billion | +47.10% |
| 2017-12-31 | NT$1.25 Billion | +4.71% |
| 2016-12-31 | NT$1.19 Billion | +1.35% |
| 2015-12-31 | NT$1.18 Billion | +6.08% |
| 2014-12-31 | NT$1.11 Billion | +10.74% |
| 2013-12-31 | NT$1.00 Billion | +8.26% |
| 2012-12-31 | NT$924.20 Million | -1.06% |
| 2011-12-31 | NT$934.09 Million | +8.40% |
| 2010-12-31 | NT$861.72 Million | -1.34% |
| 2009-12-31 | NT$873.43 Million | -- |